Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00742157 · ClinicalTrials.gov registry record · Phase 4
Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)
A Phase 4 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT00742157: Clinical Trial Phase 4 study, sponsored by University of Nebraska.
NCT00742157 is a Phase 4 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00742157, a Phase 4 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
Treatment for 3.5-8 weeks with GH (0.05 mg/kg/day) +GLN+Diet, followed by continued compliance to the individualized oral diet and enteral GLN, will result in reduced volume of TPN infusion/week and/or reduced frequency of TPN infusions/week.
Primary Outcome
Evaluate the number of participants dosed at UNMC who had a reduction in the frequency of TPN infusions/week at 6 months compared to baseline
Interventions
- DRUG Growth Hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2003-09-01 |
| Est. Completion | 2008-10-20 |
| Phase | Phase 4 |
Why NCT00742157 stopped before completion
NCT00742157 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Growth Hormone is the first listed.
NCT00742157 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00742157 about?
NCT00742157 is a clinical study titled "Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)". Treatment for 3.5-8 weeks with GH (0.05 mg/kg/day) +GLN+Diet, followed by continued compliance to the individualized oral diet and enteral GLN, will result in reduced volume of TPN infusion/week and/or reduced frequency of TPN infusions/week.
What is the current status of trial NCT00742157?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2003-09-01. Estimated completion is 2008-10-20.
What interventions are being tested in trial NCT00742157?
The interventions under investigation include: Growth Hormone (DRUG).
Who is sponsoring clinical trial NCT00742157?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00742157's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI